95
Participants
Start Date
February 3, 2021
Primary Completion Date
May 5, 2022
Study Completion Date
April 23, 2024
Pembrolizumab
Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).
Regorafenib (Stivarga, BAY73-4506)
Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.
Seoul National University Hospital, Seoul
Hospital Clínic i Provincial de Barcelona, Barcelona
AP-HM - Hopital de la Timone, Marseille
Medical Oncology Hematology Consultants, PA, Newark
Humanitas Mirasole S.p.A., Milan
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
University of Miami Miller School of Medicine, Miami
Centre François Magendie - Pessac, Pessac
Moffitt Cancer Center, Tampa
Hôpital Saint-Eloi, Montpellier
Istituto Oncologico Veneto_Padova - UOC Oncologia 1, Padua
Center Hospitalier Michallon - Grenoble, Grenoble
Heinrich-Heine-Universität Düsseldorf, Düsseldorf
Universitätsklinikum Köln, Cologne
Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy
Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz
Azienda Ospedaliero Universitaria Pisana_Santa Chiara - UO Oncologia 2, Pisa
Hopital Claude Huriez - Lille, Lille
Hôpital de la Croix Rousse, Lyon
Eberhard-Karls-Universität Tübingen, Tübingen
Klinikum der Universität München Grosshadern, München
University of Arizona Cancer Center, Tucson
USC Norris Hospital and Clinics, Los Angeles
City of Hope - Duarte Cancer Center, Duarte
Hôpital Beaujon - Clichy, Clichy
Hôpital Paul Brousse - Villejuif, Villejuif
Rambam Health Corporation, Haifa
Tel-Aviv Sourasky Medical Center, Tel Aviv
University of California Irvine Medical Center, Orange
Massachusetts General Hospital, Boston
Seattle Cancer Care Alliance, Seattle
"Rabin Medical Center , Beilinson Hospital - Internal Medicine C Department"
"Hospital General Universitario Gregorio Marañón , Digestivo"
Chiba University Hospital, Chiba
National Cancer Center Hospital East, Kashiwa
Japanese Red Cross Society Musashino Red Cross Hospital, Musashino
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Institut Català d'Oncologia Hospitalet, L'Hospitalet de Llobregat
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Bayer
INDUSTRY